Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07646418
Combined Effects of LIRT-BFR Therapy in Post- Stroke PatientsRiphah International UniversityRecruitingNot Applicable
NCT07646418Recruiting
Not Applicable
Combined Effects of LIRT-BFR Therapy in Post- Stroke PatientsRiphah International Univ...
NCT07646093
Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillectomy Pain in ChildrenHospital Universitario de CaracasCompletedNot Applicable
NCT07646093Completed
Not Applicable
Weight-Adjusted Diclofenac Potassium Medicated Lollipop for Post-Adenotonsillect...Hospital Universitario de...
NCT07645859
Comparison of High-Intensity Interval Training With Moderate-Intensity Continuous Training in Chronic Non-Specific Low Back Pain PatientsDow University of Health SciencesRecruitingNot Applicable
NCT07645859Recruiting
Not Applicable
Comparison of High-Intensity Interval Training With Moderate-Intensity Continuou...Dow University of Health...
NCT07645768
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alternative to Conventional Posterior Double Plating in Extra-Articular Distal Shaft Humeral FracturesCairo UniversityActive Not RecruitingNot Applicable
NCT07645768Active Not Recruiting
Not Applicable
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alter...Cairo University
NCT07645976
Home Environmental Risks and Caregiver AwarenessMarmara University Pendik Training and Research HospitalCompleted
NCT07645833
Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionH. Lundbeck A/SNot Yet RecruitingPhase 3
NCT07645833Not Yet Recruiting
Phase 3
Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionH. Lundbeck A/S
NCT07645521
Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation Following Functional Endoscopic Sinus SurgeryMansoura UniversityCompletedNot Applicable
NCT07645521Completed
Not Applicable
Trans-nasal Sphenopalatine Ganglion Block for Prevention of Emergence Agitation...Mansoura University
NCT07645274
Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led, Patient Navigation Program (PARTNER-MH 2.0)Indiana UniversityNot Yet RecruitingNot Applicable
NCT07645274Not Yet Recruiting
Not Applicable
Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led...Indiana University
NCT07645079
Automated Insulin Delivery Versus Daily Injections for Hospital Diabetes CareSteno Diabetes Center CopenhagenNot Yet RecruitingNot Applicable
NCT07645079Not Yet Recruiting
Not Applicable
Automated Insulin Delivery Versus Daily Injections for Hospital Diabetes CareSteno Diabetes Center Cop...
NCT07645378
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South AfricaCentre for the AIDS Programme of Research in South AfricaNot Yet RecruitingNot Applicable
NCT07645378Not Yet Recruiting
Not Applicable
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervica...Centre for the AIDS Progr...
NCT07644481
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingNot Applicable
NCT07644481Not Yet Recruiting
Not Applicable
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melpha...Institute of Hematology &...
NCT07646223
Vancomycin Efficacy in Response to Dysbiosis in Atypical ColitisFimlab laboratoriesNot Yet RecruitingPhase 2
NCT07646223Not Yet Recruiting
Phase 2
Vancomycin Efficacy in Response to Dysbiosis in Atypical ColitisFimlab laboratories
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07644312
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPGNationwide Children's HospitalNot Yet RecruitingPhase 2
NCT07644312Not Yet Recruiting
Phase 2
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG...Nationwide Children's Hos...
NCT07646535
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary AldosteronismShenzhen Salubris Pharmaceuticals Co., Ltd.Not Yet RecruitingPhase 2
NCT07646535Not Yet Recruiting
Phase 2
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses i...Shenzhen Salubris Pharmac...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07644923
Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated CoagulationNYU Langone HealthNot Yet RecruitingPhase 4
NCT07644923Not Yet Recruiting
Phase 4
Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled Wit...NYU Langone Health
NCT07644559
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerVerastem, Inc.RecruitingPhase 2
NCT07644559Recruiting
Phase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerVerastem, Inc.
NCT07646483
Clinical Trial to Evaluate the Efficacy and Safety of Conjuran® After First and Second Cycle (Repeat) Administration in Patients With Knee OsteoarthritisPharmaResearch Co.,LtdNot Yet RecruitingNot Applicable
NCT07646483Not Yet Recruiting
Not Applicable
Clinical Trial to Evaluate the Efficacy and Safety of Conjuran® After First and...PharmaResearch Co.,Ltd
Result Breakdown
Not yet recruiting12 (60%)
Recruiting4 (20%)
Completed3 (15%)
Active, not recruiting1 (5%)
not_applicable10 (50%)
Phase 25 (25%)
Phase 12 (10%)
Not Specified1 (5%)
Phase 31 (5%)
Phase 41 (5%)